Stoke Therapeutics has the GF Score of 42, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Stoke Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Stoke Therapeutics (FRA:0GT) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Stoke Therapeutics GF Score Related Terms
FRA:0GT vs VRDN, ZLAB, NUVB: GF Score Comparison
For the Biotechnology subindustry, Stoke Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's GF Score falls into.
Stoke Therapeutics (FRA:0GT) has a GF Score of 42 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Stoke Therapeutics and its competitors. This is 40% above median its historical median of 30.00. Over the past decade, Stoke Therapeutics' GF Score has ranged from 14.00 to 58.00.
Is Stoke Therapeutics' GF Score too high?
Stoke Therapeutics' current GF Score of 42 is 40% above median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 58.00. Overall, Stoke Therapeutics has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' GF Score compare to VRDN and ZLAB?
Stoke Therapeutics' GF Score of 42 can be compared against companies in the Biotechnology industry. Historically, Stoke Therapeutics' own GF Score has ranged from 14.00 to 58.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current GF Score is 42, which is 40% above median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (FRA:0GT) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.52, compared to a current price of €28.14 — trading 230.3% above its estimated fair value. The current GF Score is 42, which is 40% above median its 10-year median of 30.00. Stoke Therapeutics' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Stoke Therapeutics (FRA:0GT), the current GF Score is 42 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (FRA:0GT) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of €28.14 is trading 230.3% above its estimated GF Value™ of €8.52.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:0GT:
GF Score: 42 (40% above median its 10-year median of 30.00)
GF Value™: €8.52 vs. price of €28.14 (230.3% above fair value)
No single metric tells the full story. See the FRA:0GT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
42GF Score
Get the complete analysis for FRA:0GT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GT has been successfully added to your 